We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers includ... Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor. Show more
The major U.S. index futures are currently pointing to modestly lower open on Tuesday, with stocks likely to give back ground after ending the previous session mostly higher. Uncertainty ahead of...
Third-Quarter Performance Driven by Focused Commercial Execution and Robust Double-Digit Revenue Growth Across Product Portfolio Raises Full-Year 2024 Revenue Guidance(1) to a Range of $61.0 to...
U.S. index futures rose in Tuesday’s pre-market as investors anticipate key corporate earnings. Reports from companies like Pfizer (NYSE:PFE), McDonald’s (NYSE:MCD), and later Alphabet...
The major U.S. index futures are currently pointing to initial strength on Wall Street on Monday, with stocks likely to move mostly higher after turning in a mixed performance last week. Early...
Millions of newly eligible U.S. adults aged 50 to 64 now recommended to receive vaccination against invasive pneumococcal disease (IPD) and pneumococcal pneumonia1 Pfizer Inc. (NYSE: PFE...
First and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 Approval based on data from pivotal Phase 3 trial in adults at increased risk of lower respiratory...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.5201 | -1.81599162011 | 28.64 | 29.17 | 28.025 | 49431516 | 28.50420838 | CS |
4 | -0.2201 | -0.776640790402 | 28.34 | 30.43 | 28.025 | 34412764 | 28.9616762 | CS |
12 | -0.5301 | -1.8502617801 | 28.65 | 30.43 | 27.85 | 29637395 | 28.97845143 | CS |
26 | 1.7904 | 6.79997721187 | 26.3295 | 31.54 | 26.02 | 33625014 | 28.83446434 | CS |
52 | -2.4401 | -7.98462041885 | 30.56 | 31.54 | 25.2 | 37918597 | 28.24033758 | CS |
156 | -16.0201 | -36.2938377889 | 44.14 | 61.71 | 25.2 | 30430989 | 38.58490221 | CS |
260 | -10.5601 | -27.3011892451 | 38.68 | 61.71 | 25.2 | 30360226 | 38.38715525 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions